Biosyent Inc. (CVE:RX) – Cormark issued their Q3 2016 earnings estimates for Biosyent in a research report issued to clients and investors on Thursday. Cormark analyst D. Novak expects that the brokerage will post earnings of $0.08 per share for the quarter. Cormark also issued estimates for Biosyent’s Q4 2016 earnings at $0.07 EPS, FY2016 earnings at $0.28 EPS, FY2017 earnings at $0.32 EPS and FY2018 earnings at $0.37 EPS.

About Biosyent

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with's FREE daily email newsletter.